Pharmacists’ Role in Optimizing Medication Use in Patients with Heart Failure
DOI:
https://doi.org/10.22399/ijcesen.4566Keywords:
Pharmacists, heart failure, medication optimization, patient management, drug interactions, medication adherenceAbstract
Pharmacists play a crucial role in the management of patients with heart failure (HF) by optimizing medication therapies tailored to individual patient needs. Their extensive knowledge of pharmacotherapy allows them to conduct comprehensive medication reviews, identify potential drug interactions, and monitor for side effects, which is essential in this population that often requires multiple medications. By collaborating with healthcare providers and engaging in interdisciplinary team approaches, pharmacists help ensure that patients are prescribed the most effective treatment regimens, adhering to clinical guidelines such as those from the American College of Cardiology and the American Heart Association. Their involvement can lead to improved medication adherence, reduced hospital readmissions, and overall better patient outcomes. Moreover, pharmacists support heart failure management by providing patient education and counseling about the importance of medication adherence, lifestyle changes, and self-monitoring. They can empower patients to understand their treatment regimens, recognize signs of worsening heart failure, and know when to seek medical advice. Through medication therapy management (MTM) services, pharmacists can also tailor interventions that address barriers to adherence, such as cost, complexity of regimens, and patient health literacy. This proactive approach not only enhances the quality of life for patients living with heart failure but also contributes to the healthcare system by reducing overall costs associated with complications and hospitalizations.
References
[1] Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J Suppl. 2016;18:G43–G52.
[2] Cheng JW. Current perspectives on the role of the pharmacist in heart failure management. Integr Pharm Res Pract. 2018;7:1–11. doi: 10.2147/IPRP.S137882.
[3] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893. doi: 10.1056/NEJMoa1915928.
[4] Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving treatment adherence in heart failure. Dtsch Arztebl Int. 2016;113:423–430. doi: 10.3238/arztebl.2016.0423.
[5] Sizar O, Podder V, Talati R. Empagliflozin. Treasure Island: StatPearls Publishing; 2023.
[6] Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail. 2021;3:224–236. doi: 10.36628/ijhf.2021.0023.
[7] Omboni S, Caserini M. Effectiveness of pharmacist’s intervention in the management of cardiovascular diseases. Open Heart. 2018;5:e000687. doi: 10.1136/openhrt-2017-000687.
[8] Ponikowski P, Anker SD, AlHabib KF, et al. Heart Failure Preventing Disease and Death Worldwide. Sophia Antipolis: European Society of Cardiology; 2014.
[9] Shah SP, Dixit NM, Mendoza K, et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc (2003) 2022;62:575–579.e2. doi: 10.1016/j.japh.2021.11.012.
[10] Heart Online. Adverse drug reactions and heart failure. Sydney: National Heart Foundation of Australia; 2014.
[11] de Araújo BC, de Melo RC, de Bortoli MC, Bonfim JR, Toma TS. How to prevent or reduce prescribing errors: an evidence brief for policy. Front Pharmacol. 2019;10:439. doi: 10.3389/fphar.2019.00439.
[12] Page RL, 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–e69. doi: 10.1161/CIR.0000000000000426.
[13] Patibandla S, Heaton J, Kyaw H. Spironolactone. Treasure Island: StatPearls Publishing; 2022.
[14] Lugo Zamora IL, Lloyd C, Lorenzo-Castro S, Mussenden C, Hale G. Utilizing pharmacist-led telehealth services in ambulatory patients with heart failure. Innov Pharm. 2023;14:12. doi: 10.24926/iip.v14i1.5306.
[15] Food and Drug Administration. Highlights of Prescribing Information: Dapagliflozin. Silver Spring: Food and Drug Administration; 2021.
[16] Hargraves TL, Bennet AA, Brien JE. Developing an outpatient heart failure pharmacy service. J Pharm Pract Res. 2008;38:13–16.
[17] Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–1356. doi: 10.1002/ejhf.1858.
[18] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032. doi: 10.1161/CIR.0000000000001063.
[19] Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart failure management. Heart. 2018;104:1376–1382. doi: 10.1136/heartjnl-2016-310598.
[20] Food and Drug Administration. Highlights of Prescribing Information: Coreg (Carvedilol). Silver Spring: Food and Drug Administration; 1995.
[21] Speranza-Sánchez M, Zavaleta-Monestel E, Sancho-Zumbado S, Arguedas-Chacón S, Quirós-Romero A. From end-of-life care to improved quality of life and better prognosis by using vericiguat: a case report from Costa Rica. Cureus. 2023;15:e39570. doi: 10.7759/cureus.39570.
[22] Riello RJ., III. Heart failure with reduced ejection fraction. In: PSAP 2022 Book – Cardiology. Gale SM, editor. Lenexa: American College of Clinical Pharmacy; 2022.
[23] Food and Drug Administration. Metoprolol Succinate. Silver Spring: Food and Drug Administration; 2006.
[24] Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther. 2017;102:209–212. doi: 10.1002/cpt.687.
[25] Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci. 2022;7:504–517. doi: 10.1016/j.jacbts.2021.10.018.
[26] Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail. 2023;10:1961–1971. doi: 10.1002/ehf2.14367.
[27] Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251–2262. doi: 10.1001/jama.2015.15734.
[28] Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm. 2014;20:741–755. doi: 10.18553/jmcp.2014.20.7.741.
[29] European Heart Network. Heart Failure and Cardiovascular Diseases – A European Heart Network Paper. Brussels: European Heart Network; 2019.
[30] Schumacher PM, Becker N, Tsuyuki RT, et al. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2021;8:3566–3576. doi: 10.1002/ehf2.13508.
[31] Aizpuru F, Millán E, Garmendia I, Mateos M, Librero J. Hospitalizations for heart failure: epidemiology and health system burden based on data gathered in routine practice. Med Clínica Práctica. 2020;3:100140.
[32] Mesquita ET, Jorge AJ, Rabelo LM, Souza CV., Jr Understanding hospitalization in patients with heart failure. Int J Cardiovasc Sci. 2017;30:81–90.
[33] Hargraves TL, Bennett AA, Brien JE. Evaluating outpatient pharmacy services: a literature review of specialist heart failure services. Int J Pharm Pract. 2010;14:3–9.
[34] Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999;159:1939–1945. doi: 10.1001/archinte.159.16.1939.
[35] Lee H, Oh SH, Cho H, Cho HJ, Kang HY. Prevalence and socio-economic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord. 2016;16:215. doi: 10.1186/s12872-016-0404-2.
[36] Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128:1421–1434. doi: 10.1161/CIRCRESAHA.121.318172.
[37] Lynch KA, Ganz DA, Saliba D, Chang DS, de Peralta SS. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integration. BMJ Open Qual. 2022;11:e001901. doi: 10.1136/bmjoq-2022-001901.
[38] Osenenko KM, Kuti E, Deighton AM, Pimple P, Szabo SM. Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm. 2022;28:157–167. doi: 10.18553/jmcp.2022.28.2.157.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering

This work is licensed under a Creative Commons Attribution 4.0 International License.